Enveda Biosciences, a biotechnology company harnessing nature’s chemistry to develop next-generation small molecule therapies, has added three leaders to further scale and accelerate its translational drug development efforts.   Dr. John Wetterau, Dr. Kendra Hightower and Dr. Don Hertzog will play a vital role in validating and advancing the growing number of pathways, targets and leads identified by Enveda’s natural chemistry drug discovery engine.   “Our priority during the past few years ...